Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Sara Lonardi, MD
Aparna R. Parikh, MD
Alan Venook, MD
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Management of HER2-Low MBC Following First-Line Disease Progression
The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Expert Viewpoint: Optimizing Breast Cancer Treatment
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.